logo
  

Stock Alert: Vertex Pharma Tanks 15% On Stopping Development Of Protein-deficiency Drug

Shares of Vertex Pharmaceuticals Incorporated (VRTX) are falling more than 15% Thursday morning after the company said it has decided to stop the development of its protein-deficiency drug candidate VX-814.

VX-814 was in phase II study in patients with alpha-1 antitrypsin deficiency.

Vertex Pharmaceuticals stock is currently at $229.78. It has been trading in the range of $173.62- $306.08 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT